Phase 1-2 trial of Gamunex (intravenous gammaglobulin) for Sickle Cell Acute Pain

Medicine & Life Sciences

1. Intravenous Immunoglobulins 100%
2. Acute Pain 95%
3. Leukocytes 70%
4. Endothelium 59%
5. Narcotics 51%
6. Research Personnel 46%
7. Cell Communication 42%
8. Erythrocytes 35%
9. Hospitalization 33%
10. Placebos 30%
11. adhesion receptor 29%
12. Hemoglobinopathies 28%
13. Organized Financing 26%
14. Sickle Cell Anemia 24%
15. Hemolysis 23%
16. National Institutes of Health (U.S.) 23%
17. Standard of Care 21%
18. Hispanic Americans 21%
19. African Americans 21%
20. Saline Solution 20%
21. Economics 17%
22. Psychology 15%
23. Biomarkers 14%
24. Pathology 14%
25. Blood Vessels 13%
26. Safety 13%
27. Pain 12%
28. Survival 12%
29. Serum 10%